+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Post-operative Nausea and Vomiting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851990
  • Report
  • Region: Global
  • 166 pages
  • Transparency Market Research
1 of 2

Post-operative Nausea and Vomiting (PONV) Market - Overview

This report studies the current as well as future prospects of the global post-operative nausea and vomiting (PONV) market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and provision of drug therapies as well as devices for treatment, and new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global post-operative nausea and vomiting (PONV) market with respect to the leading market segments based on treatment type, distribution channel, and region.

The global post-operative nausea and vomiting market has been segmented based on treatment type, distribution channel, and region. In terms of treatment type, the market has been classified into serotonin antagonists, steroids, dopamine antagonists, nk-1 receptor antagonists, others, and non-pharmacological treatment. Based on distribution channel, the global post-operative nausea and vomiting (PONV) market has been divided into hospital pharmacies, online pharmacies, and retail pharmacies and drug stores.

Each of the market segments has been extensively analyzed based on market-related factors such as increase in incidence rate of PONV in surgical patient population and rise in adoption rate of non-pharmacological methods of treatment. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the PONV market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global PONV market.

Geographically, the global PONV market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global PONV market.

Major players operating in the global PONV market are Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi, Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Trends
5.5. Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016-2026
5.6. Global Post-operative Nausea and Vomiting (PONV) Market Outlook

Chapter 6 Market Outlook
6.1. Absolute Surgical Procedure Volume, by Region
6.2. Incidence of Post-operative Nausea and Vomiting, by Region, (2017 - Estimated)
6.3. Post-operative Nausea and Vomiting (PONV) Market: Pipeline Analysis

Chapter 7 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
7.3.1. Serotonin Antagonists
7.3.2. Steroids
7.3.3. Dopamine Antagonists
7.3.4. NK-1 receptor Antagonists
7.3.5. Non-Pharmacologic Treatment
7.4. Market Attractiveness Analysis, by Treatment Type

Chapter 8 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Global PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
8.2.1. Hospital Pharmacies
8.2.2. Online Pharmacies
8.2.3. Retail Pharmacies and Drug Stores
8.3. Global PONV Market Attractiveness Analysis, by Distribution Channel
8.4. Key Trends

Chapter 9 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global PONV Market Value (US$ Mn) Forecast, by Region, 2018-2026
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global PONV Market Attractiveness Analysis, by Region

Chapter 10 North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Key Findings
10.2. North America PONV Market Size (US$ Mn) Forecast, by Country, 2018-2026
10.2.1. U.S.
10.2.2. Canada
10.3. North America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
10.3.1. Serotonin Antagonists
10.3.2. Steroids
10.3.3. Dopamine Antagonists
10.3.4. NK-1 receptor Antagonists
10.3.5. Non-pharmacologic Treatment
10.4. North America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
10.4.1. Hospital Pharmacies
10.4.2. Online Pharmacies
10.4.3. Retail Pharmacies and Drug Stores
10.5. North America PONV Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Treatment Type
10.5.3. By Distribution Channel

Chapter 11 Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Key Findings
11.2. Europe PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Europe PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
11.3.1. Serotonin Antagonists
11.3.2. Steroids
11.3.3. Dopamine Antagonists
11.3.4. NK-1 receptor Antagonists
11.3.5. Non-Pharmacologic Treatment
11.4. Europe PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
11.4.1. Hospital Pharmacies
11.4.2. Online Pharmacies
11.4.3. Retail Pharmacies and Drug Stores
11.5. Europe PONV Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Treatment Type
11.5.3. By Distribution Channel

Chapter 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Key Findings/Developments
12.2. Market Overview
12.3. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
12.4.1. Serotonin Antagonists
12.4.2. Steroids
12.4.3. Dopamine Antagonists
12.4.4. NK-1 receptor Antagonists
12.4.5. Non-Pharmacologic Treatment
12.5. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
12.5.1. Hospital Pharmacies
12.5.2. Online Pharmacies
12.5.3. Retail Pharmacies and Drug Stores
12.6. Asia Pacific PONV Market Attractiveness Analysis
12.6.1. By Country
12.6.2. By Treatment Type
12.6.3. By Distribution Channel

Chapter 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Key Findings/Developments
13.2. Market Overview
13.3. Latin America PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
13.4.1. Serotonin Antagonists
13.4.2. Steroids
13.4.3. Dopamine Antagonists
13.4.4. NK-1 receptor Antagonists
13.4.5. Non-Pharmacologic Treatment
13.5. Latin America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
13.5.1. Hospital Pharmacies
13.5.2. Online Pharmacies
13.5.3. Retail Pharmacies and Drug Stores
13.6. Latin America PONV Market Attractiveness Analysis
13.6.1. By Country
13.6.2. By Treatment Type
13.6.3. By Distribution Channel

Chapter 14 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
14.1. Key Findings/Developments
14.2. Market Overview
14.3. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2026
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Israel
14.3.4. Rest of Middle East & Africa
14.4. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2026
14.4.1. Serotonin Antagonists
14.4.2. Steroids
14.4.3. Dopamine Antagonists
14.4.4. NK-1 receptor Antagonists
14.4.5. Non-Pharmacologic Treatment
14.5. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2026
14.5.1. Hospital Pharmacies
14.5.2. Online Pharmacies
14.5.3. Retail Pharmacies and Drug Stores
14.6. Middle East & Africa PONV Market Attractiveness Analysis
14.6.1. By Country
14.6.2. By Treatment Type
14.6.3. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Key Players and Their Competitive Positioning
15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
15.3.1. Acacia Pharma
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. F. Hoffmann La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. ANI Pharmaceuticals
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GlaxoSmithKline Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eisai Co., Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck KGaA
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Helsinn Holding Co.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Camurus AB
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll